Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction

Clinical and Experimental Hypertension : CHE
Shunsuke KiuchiTakanori Ikeda

Abstract

It is unclear that the difference in efficacy of tolvaptan (TLV) on the length of hospital stay for both heart failure (HF) preserved ejection fraction (EF) (HFpEF) and reduced EF (HFrEF) patients. We investigated 369 patients who were hospitalized with HF from February 2011 to June 2016 and initiated TLV. Patients who died in hospital, transferred hospital or clinical scenario 4 or 5 were excluded. Finally, we analyzed 108 patients with HFpEF and 96 patients with HFrEF. We evaluated the relationship between the length of hospital stay and the date of TLV initiation. Moreover, we compared the early use (within the median) and delayed use (the median or later) of TLV. The date of TLV initiation was statistically associated with the length of hospital stay in both HFpEF and HFrEF (HFpEF: r = 0.625, P < 0.001, HFrEF: r = 0.618, P < 0.001). In HFpEF, the length of hospital stay in delayed use group was significantly longer than the early use group (22.2 ± 10.7 days and 38.1 ± 22.6 days, P < 0.001). The result was similar in HFrEF (22.0 ± 15.0 days and 32.1 ± 22.0 days, P = 0.008). On the other hand, there were no statistically significant differences in the length of hospital stay after initiation of TLV in both HFpEF and HFrEF. Ot...Continue Reading

References

Sep 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·N B SchillerI Schnittger
Dec 23, 1971·The New England Journal of Medicine·P A McKeeW B Kannel
Jul 22, 1982·The New England Journal of Medicine·M R BristowE B Stinson
Dec 3, 2005·International Journal of Cardiology·Tomohiro NakamuraSan-e Ishikawa
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Apr 7, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Sanae HamaguchiUNKNOWN JCARE-CARD Investigators
Jun 8, 2012·Journal of Cardiovascular Medicine·Muthiah VaduganathanUNKNOWN EVEREST investigators
Jul 17, 2013·European Journal of Heart Failure·Saeed PayvarUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators
Jul 11, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Teruhiko ImamuraIssei Komuro
Jan 15, 2016·Journal of Clinical Medicine Research·Tadaaki ArimuraKeijiro Saku
Jul 12, 2016·International Heart Journal·Takanori KonoHiroyuki Tanaka
Mar 18, 2017·Journal of the American College of Cardiology·Marvin A KonstamUNKNOWN SECRET of CHF Investigators, Coordinators, and Committee Members
Jun 20, 2017·Drug Discoveries & Therapeutics·Shunsuke KiuchiTakanori Ikeda
Sep 14, 2018·Internal Medicine·Shunsuke Kiuchi, Takanori Ikeda

❮ Previous
Next ❯

Citations

Dec 28, 2019·Current Pharmaceutical Design·Carmelo ButtàAntonio Pinto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved